What are the major opportunities in the Vulvovaginal Candidiasis Treatment market? What are the strategies for the Vulvovaginal Candidiasis Treatment market?

For detailed insights on the major opportunities and strategies in the Vulvovaginal Candidiasis Treatment market, Read More

How does the Vulvovaginal Candidiasis Treatment market relate to the overall economy and other similar markets?

For detailed insights on the key dynamics influencing the Vulvovaginal Candidiasis Treatment market growth and SWOT analysis of the Vulvovaginal Candidiasis Treatment industry, Read More

Global Vulvovaginal Candidiasis Treatment Market Report 2025

Item added to cart!

Published : December 2025

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF

Purchase This Report

Vulvovaginal Candidiasis Treatment Global Market Report 2025

Name: Vulvovaginal Candidiasis Treatment Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Drug Class (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Other Drug Classes), By Route Of Administration (Oral, Intravenous, Topical), By Distribution Channel (Hospital Pharmacy , Retail Pharmacy, Online Pharmacy) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Vulvovaginal Candidiasis Treatment Market Overview

• Vulvovaginal Candidiasis Treatment market size has reached to $1.13 billion in 2024

• Expected to grow to $1.44 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%

• Growth Driver: Rising Awareness Of Vaginal Disorders Driving Market Growth

• Market Trend: Innovative Approaches In Non-Azole Medications For Fungal Infections

• North America was the largest region in 2024.

What Is Covered Under Vulvovaginal Candidiasis Treatment Market?

Vulvovaginal candidiasis treatment refers to the medical management of a common fungal infection caused by candida species, affecting the vaginal area. The treatment aims to alleviate symptoms such as itching, burning, and abnormal discharge. The primary use of these treatments is to relieve discomfort, restore balance, and prevent recurrence of the infection.

The main drugs for vulvovaginal candidiasis are clotrimazole, nystatin, fluconazole, ketoconazole, terbinafine, terconazole, and others. Clotrimazole is an antifungal medication commonly used to treat vulvovaginal candidiasis. It can be administered through oral, intravenous, and topical routes and is distributed through hospital pharmacy, retail pharmacy, and online pharmacy.

Vulvovaginal Candidiasis Treatment Market Size and growth rate 2025 to 2029: Graph

What Is The Vulvovaginal Candidiasis Treatment Market Size 2025 And Growth Rate?

The vulvovaginal candidiasis treatment market size has grown strongly in recent years. It will grow from $1.13 billion in 2024 to $1.18 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to increasing disease burden of vulvovaginal candidiasis disorder, increasing number of insurance facilities, increasing clinical trials, rising research and developmental activities, increasing usage of broad-spectrum antibiotics.

What Is The Vulvovaginal Candidiasis Treatment Market Growth Forecast?

The vulvovaginal candidiasis treatment market size is expected to see strong growth in the next few years. It will grow to $1.44 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to increasing healthcare spending, growing geriatric population, increasing prevalence of chronic diseases, growing development of new antifungal drugs, increasing awareness of vaginal disorders. Major trends in the forecast period include technological advancements, strategic collaboration, investment in research and development, advance treatment options, advanced therapies.

The forecast of 5.1% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. antifungal access by inflating prices of fluconazole generic tablets and intravaginal probiotic formulations developed in India and Denmark, resulting in recurrent infection cycles and higher outpatient gynecology costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Vulvovaginal Candidiasis Treatment Market Segmented?

1) By Drug Class: Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Other Drug Classes

2) By Route Of Administration: Oral, Intravenous, Topical

3) By Distribution Channel: Hospital Pharmacy , Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Clotrimazole: Over-the-Counter (OTC) Medications, Prescription Medications

2) By Nystatin: Monotherapy, Combination Therapy

3) By Fluconazole: Single-Dose Therapy, Multi-Dose Therapy

4) By Ketoconazole: Short-Term Treatment, Long-Term Treatment

5) By Terbinafine: Systemic Treatment, Topical Treatment

6) By Terconazole: Low-Dose Therapy, High-Dose Therapy

7) By Other Drug Classes: Azole Antifungals, Polyene Antifungals, Novel Therapeutics

What Is Driving The Vulvovaginal Candidiasis Treatment Market? Rising Awareness Of Vaginal Disorders Driving Market Growth

The rising awareness of vaginal disorders is expected to propel the growth of the vulvovaginal candidiasis treatment market going forward. Vaginal disorders refer to conditions affecting the vagina, including infections, inflammation, irritation, or abnormal discharge. Rising awareness of vaginal disorders is driven by increased education, improved access to healthcare, and a growing focus on women's health and well-being. Vulvovaginal candidiasis treatment supports vaginal disorder patients by alleviating symptoms such as itching, irritation, and abnormal discharge, restoring the natural vaginal microbiome, preventing recurrent infections, and improving overall vaginal health and comfort. For instance, in October 2024, according to the Cancer Australia, an Australia-based government agency, an estimated 123 new cancer cases of vaginal cancer diagnosed in 2022, of which 30 people died of vaginal cancer. Therefore, the rising awareness of vaginal disorders is driving the growth of the vulvovaginal candidiasis treatment industry.

Who Are The Major Players In The Global Vulvovaginal Candidiasis Treatment Market?

Major companies operating in the vulvovaginal candidiasis treatment market are Pfizer Inc., Bayer Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Limited, Cipla Limited, Zydus Lifesciences, Novartis Pharmaceuticals Inc., Glenmark Pharmaceuticals Ltd., Shandong Boyuan Pharmaceutical, Taro Pharmaceuticals Industries Ltd., Accord Healthcare Ltd., Incepta Pharmaceuticals Ltd., Cosette Pharmaceuticals Inc., Crescent Pharma Ltd., Bhumi Pharmaceuticals, Cidara Therapeutics Inc., Avet Pharmaceuticals Inc., Austell Pharmaceuticals Ltd., Laboratoire Riva Inc., Cadila Pharmaceuticals

What Are The Key Trends Of The Global Vulvovaginal Candidiasis Treatment Market? Innovative Approaches In Non-Azole Medications For Fungal Infections

Major companies operating in the vulvovaginal candidiasis treatment market are focusing on novel pharmaceuticals, such as an oral and non-azole medication, to enhance treatment effectiveness and patient convenience. Oral and non-azole medication refers to antifungal drugs taken orally that do not belong to the azole class, offering an alternative treatment for fungal infections. For instance, in December 2022, Scynexis Inc., a US-based biotechnology company, announced BREXAFEMME (ibrexafungerp tablets), an oral and non-azole medication, for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC) approved by the Food and Drug Administration (FDA), a US-based government agency. BREXAFEMME is the first and only FDA-approved therapy for both the treatment of vulvovaginal candidiasis (VVC) and the reduction in the incidence of recurrent VVC. This approval positions BREXAFEMME as a key treatment option for patients with recurrent infections, offering a novel approach to managing RVVC.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Vulvovaginal Candidiasis Treatment Market? Mycovia Pharmaceuticals And Jiangsu Hengrui Partner To Launch VIVJOA In China For Severe VVC Treatment

In February 2024, Mycovia Pharmaceuticals Inc., a US-based pharmaceutical company collaborated with Jiangsu Hengrui Pharmaceuticals Co. Ltd. to launch VIVJOA (oteseconazole) capsules in China for treating severe vulvovaginal candidiasis (VVC). With this partnership, Mycovia Pharmaceuticals Inc. and Jiangsu Hengrui Pharmaceuticals Co. Ltd. aim to provide an effective treatment for severe vulvovaginal candidiasis (VVC), addressing the unmet medical needs of patients, and enhancing therapeutic options for long-term fungal infection management. Jiangsu Hengrui Pharmaceuticals Co. Ltd. is a China-based company that offers treatment for vulvovaginal candidiasis (VVC).

What Is The Regional Outlook For The Global Vulvovaginal Candidiasis Treatment Market?

North America was the largest region in the vulvovaginal candidiasis treatment market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Vulvovaginal Candidiasis Treatment Market?

The vulvovaginal candidiasis treatment market consists of sales of antifungal creams, oral antifungal capsules, suppositories, vaginal gels, pessaries, and non-azole medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Vulvovaginal Candidiasis Treatment Industry?

The vulvovaginal candidiasis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vulvovaginal candidiasis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

Vulvovaginal Candidiasis Treatment Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$1.18 billion
Revenue Forecast In 2034	$1.44 billion
Growth Rate	CAGR of 5.1% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The vulvovaginal candidiasis treatment market covered in this report is segmented – 1) By Drug Class: Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Other Drug Classes 2) By Route Of Administration: Oral, Intravenous, Topical 3) By Distribution Channel: Hospital Pharmacy , Retail Pharmacy, Online Pharmacy Subsegments: 1) By Clotrimazole: Over-the-Counter (OTC) Medications, Prescription Medications 2) By Nystatin: Monotherapy, Combination Therapy 3) By Fluconazole: Single-Dose Therapy, Multi-Dose Therapy 4) By Ketoconazole: Short-Term Treatment, Long-Term Treatment 5) By Terbinafine: Systemic Treatment, Topical Treatment 6) By Terconazole: Low-Dose Therapy, High-Dose Therapy 7) By Other Drug Classes: Azole Antifungals, Polyene Antifungals, Novel Therapeutics
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., Bayer Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Limited, Cipla Limited, Zydus Lifesciences, Novartis Pharmaceuticals Inc., Glenmark Pharmaceuticals Ltd., Shandong Boyuan Pharmaceutical, Taro Pharmaceuticals Industries Ltd., Accord Healthcare Ltd., Incepta Pharmaceuticals Ltd., Cosette Pharmaceuticals Inc., Crescent Pharma Ltd., Bhumi Pharmaceuticals, Cidara Therapeutics Inc., Avet Pharmaceuticals Inc., Austell Pharmaceuticals Ltd., Laboratoire Riva Inc., Cadila Pharmaceuticals
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Vulvovaginal Candidiasis Treatment Market Characteristics

3. Vulvovaginal Candidiasis Treatment Market Trends And Strategies

4. Vulvovaginal Candidiasis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Vulvovaginal Candidiasis Treatment Growth Analysis And Strategic Analysis Framework

5.1. Global Vulvovaginal Candidiasis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Vulvovaginal Candidiasis Treatment Market Growth Rate Analysis

5.4. Global Vulvovaginal Candidiasis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Vulvovaginal Candidiasis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Vulvovaginal Candidiasis Treatment Total Addressable Market (TAM)

6. Vulvovaginal Candidiasis Treatment Market Segmentation

6.1. Global Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Clotrimazole

Nystatin

Fluconazole

Ketoconazole

Terbinafine

Terconazole

Other Drug Classes

6.2. Global Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral

Intravenous

Topical

6.3. Global Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

6.4. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Clotrimazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Over-the-Counter (OTC) Medications

Prescription Medications

6.5. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Nystatin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Monotherapy

Combination Therapy

6.6. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Fluconazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Single-Dose Therapy

Multi-Dose Therapy

6.7. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Ketoconazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Short-Term Treatment

Long-Term Treatment

6.8. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Terbinafine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Systemic Treatment

Topical Treatment

6.9. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Terconazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Low-Dose Therapy

High-Dose Therapy

6.10. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Azole Antifungals

Polyene Antifungals

Novel Therapeutics

7. Vulvovaginal Candidiasis Treatment Market Regional And Country Analysis

7.1. Global Vulvovaginal Candidiasis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Vulvovaginal Candidiasis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vulvovaginal Candidiasis Treatment Market

8.1. Asia-Pacific Vulvovaginal Candidiasis Treatment Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vulvovaginal Candidiasis Treatment Market

9.1. China Vulvovaginal Candidiasis Treatment Market Overview

9.2. China Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vulvovaginal Candidiasis Treatment Market

10.1. India Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vulvovaginal Candidiasis Treatment Market

11.1. Japan Vulvovaginal Candidiasis Treatment Market Overview

11.2. Japan Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vulvovaginal Candidiasis Treatment Market

12.1. Australia Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vulvovaginal Candidiasis Treatment Market

13.1. Indonesia Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vulvovaginal Candidiasis Treatment Market

14.1. South Korea Vulvovaginal Candidiasis Treatment Market Overview

14.2. South Korea Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vulvovaginal Candidiasis Treatment Market

15.1. Western Europe Vulvovaginal Candidiasis Treatment Market Overview

15.2. Western Europe Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vulvovaginal Candidiasis Treatment Market

16.1. UK Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vulvovaginal Candidiasis Treatment Market

17.1. Germany Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vulvovaginal Candidiasis Treatment Market

18.1. France Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vulvovaginal Candidiasis Treatment Market

19.1. Italy Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vulvovaginal Candidiasis Treatment Market

20.1. Spain Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vulvovaginal Candidiasis Treatment Market

21.1. Eastern Europe Vulvovaginal Candidiasis Treatment Market Overview

21.2. Eastern Europe Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vulvovaginal Candidiasis Treatment Market

22.1. Russia Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vulvovaginal Candidiasis Treatment Market

23.1. North America Vulvovaginal Candidiasis Treatment Market Overview

23.2. North America Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vulvovaginal Candidiasis Treatment Market

24.1. USA Vulvovaginal Candidiasis Treatment Market Overview

24.2. USA Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vulvovaginal Candidiasis Treatment Market

25.1. Canada Vulvovaginal Candidiasis Treatment Market Overview

25.2. Canada Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vulvovaginal Candidiasis Treatment Market

26.1. South America Vulvovaginal Candidiasis Treatment Market Overview

26.2. South America Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vulvovaginal Candidiasis Treatment Market

27.1. Brazil Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vulvovaginal Candidiasis Treatment Market

28.1. Middle East Vulvovaginal Candidiasis Treatment Market Overview

28.2. Middle East Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vulvovaginal Candidiasis Treatment Market

29.1. Africa Vulvovaginal Candidiasis Treatment Market Overview

29.2. Africa Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vulvovaginal Candidiasis Treatment Market Competitive Landscape And Company Profiles

30.1. Vulvovaginal Candidiasis Treatment Market Competitive Landscape

30.2. Vulvovaginal Candidiasis Treatment Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Bayer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Dr. Reddy's Laboratories Limited Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Cipla Limited Overview, Products and Services, Strategy and Financial Analysis

31. Vulvovaginal Candidiasis Treatment Market Other Major And Innovative Companies

31.1. Zydus Lifesciences

31.2. Novartis Pharmaceuticals Inc.

31.3. Glenmark Pharmaceuticals Ltd.

31.4. Shandong Boyuan Pharmaceutical

31.5. Taro Pharmaceuticals Industries Ltd.

31.6. Accord Healthcare Ltd.

31.7. Incepta Pharmaceuticals Ltd.

31.8. Cosette Pharmaceuticals Inc.

31.9. Crescent Pharma Ltd.

31.10. Bhumi Pharmaceuticals

31.11. Cidara Therapeutics Inc.

31.12. Avet Pharmaceuticals Inc.

31.13. Austell Pharmaceuticals Ltd.

31.14. Laboratoire Riva Inc.

31.15. Cadila Pharmaceuticals

32. Global Vulvovaginal Candidiasis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vulvovaginal Candidiasis Treatment Market

34. Recent Developments In The Vulvovaginal Candidiasis Treatment Market

35. Vulvovaginal Candidiasis Treatment Market High Potential Countries, Segments and Strategies

35.1 Vulvovaginal Candidiasis Treatment Market In 2029 - Countries Offering Most New Opportunities

35.2 Vulvovaginal Candidiasis Treatment Market In 2029 - Segments Offering Most New Opportunities

35.3 Vulvovaginal Candidiasis Treatment Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Clotrimazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Nystatin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Fluconazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Ketoconazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Terbinafine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Terconazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Global Vulvovaginal Candidiasis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Global Vulvovaginal Candidiasis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: Asia-Pacific, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: Asia-Pacific, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: China, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: China, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: India, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: India, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Japan, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Japan, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Australia, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Australia, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: Indonesia, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: Indonesia, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: South Korea, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: South Korea, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: Western Europe, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: Western Europe, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: UK, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: UK, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: Germany, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: Germany, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: France, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: France, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Italy, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Italy, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Spain, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Spain, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Eastern Europe, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Eastern Europe, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: Russia, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: Russia, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: North America, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: North America, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: USA, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: USA, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: Canada, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: Canada, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: South America, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: South America, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Brazil, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Brazil, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Middle East, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Middle East, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Africa, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 80: Africa, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 81: Pfizer Inc. Financial Performance

Table 82: Bayer Inc. Financial Performance

Table 83: Teva Pharmaceutical Industries Ltd. Financial Performance

Table 84: Dr. Reddy's Laboratories Limited Financial Performance

Table 85: Cipla Limited Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Clotrimazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Nystatin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Fluconazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Ketoconazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Terbinafine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Terconazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Global Vulvovaginal Candidiasis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Global Vulvovaginal Candidiasis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: Asia-Pacific, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: Asia-Pacific, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: China, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: China, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: India, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: India, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Japan, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Japan, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Australia, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Australia, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: Indonesia, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: Indonesia, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: South Korea, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: South Korea, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: Western Europe, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: Western Europe, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: UK, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: UK, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: Germany, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: Germany, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: France, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: France, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Italy, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Italy, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Spain, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Spain, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Eastern Europe, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Eastern Europe, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: Russia, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: Russia, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: North America, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: North America, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: USA, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: USA, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: Canada, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: Canada, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: South America, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: South America, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Brazil, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Brazil, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Middle East, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Middle East, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Africa, Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 80: Africa, Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 81: Pfizer Inc. Financial Performance

Figure 82: Bayer Inc. Financial Performance

Figure 83: Teva Pharmaceutical Industries Ltd. Financial Performance

Figure 84: Dr. Reddy's Laboratories Limited Financial Performance

Figure 85: Cipla Limited Financial Performance

From Insight to Impact: Strategic Growth Mapping in the HER2-Positive Breast Cancer Market

Hospital And Nursing Home Probiotics Market Overview 2025: Competitive Shifts, Forecast Models, and Emerging Opportunities

Next-Gen Implantable Cardioverter Defibrillators (ICDs) : Market Forecast, Transformation, and Long-Term Trajectories

Indwelling Catheters Growth Trajectory: Key Forecasts and Strategic Insights

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Explore the latest trends, growth insights, and forecasts in the Key Trend Shaping The Ophthalmology Medical Service Market.

Candidiasis Therapeutics Global Market Report 2025 – By Treatment Type (Medication, Surgery, Other Treatments), By Anatomy Type (Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Sy...

Vulvodynia Treatment Global Market Report 2025 – By Drug Type (Anticonvulsants, Tricyclic Antidepressants, Local Anesthetics, Antimicrobials, Hormone Creams, Nerve Blocks, Other Drug Types), By Route of Administration (O...

Vaginitis Therapeutics Global Market Report 2025 – By Drug Type (Nitroimidazole Compound, Lincosamide Antibiotics, Triazoles, Imidazoles), By Route Of Administration (Oral, Cutaneous, Vaginal), By Indication Type (Bacter...

Vaginal Rejuvenation Global Market Report 2025 – By Type (Surgical, Non-Surgical), By Treatment Type (Reconstructive Vaginal Rejuvenation, Cosmetic Vaginal Rejuvenation), By Application (Incontinence, Aesthetic Purposes,...

Systemic Aspergillosis And Systemic Candidiasis Global Market Report 2025 – By Type (Systemic Oral Azoles, Voriconazole, Liposomal Amphotericin B, Topical Antifungal Agents, Other Types), By Application (Allergic Broncho...

Specialty Yeast Global Market Report 2025 – By Type (Yeast Extract, Yeast Autolysate, Yeast Beta-Glucan, Other Type), By Species (Saccharomyces Cerevisiae, Pichia Pastoris, Kluyveromyces, Other Species), By Application (...

Antifungals Global Market Report 2025 – By Drug Type (Echinocandins, Azoles, Polyenes, Allylamines), By Route of Administration (Oral, Parenteral, Topical), By End users (Hospitals & Clinics, Dermatology clinics, Other U...

Frequently Asked Questions

What is the definition of the Vulvovaginal Candidiasis Treatment market?

How will the Vulvovaginal Candidiasis Treatment market drivers and restraints affect the market dynamics? What forces will shape the Vulvovaginal Candidiasis Treatment industry going forward?

The market major growth driver - Rising Awareness Of Vaginal Disorders Driving Market Growth. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the Vulvovaginal Candidiasis Treatment market?

The vulvovaginal candidiasis treatment market size has grown steadily in recent years. It will grow from $1.13 billion in 2024 to $1.18 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to increasing disease burden of vulvovaginal candidiasis disorder, increasing number of insurance facilities, increasing clinical trials, rising research and developmental activities, increasing usage of broad-spectrum antibiotics. The vulvovaginal candidiasis treatment market size is expected to see strong growth in the next few years. It will grow to " $1.44 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to increasing healthcare spending, growing geriatric population, increasing prevalence of chronic diseases, growing development of new antifungal drugs, increasing awareness of vaginal disorders. Major trends in the forecast period include technological advancements, strategic collaboration, investment in research and development, advance treatment options, advanced therapies. For further insights on this market, request a sample here

How is the Vulvovaginal Candidiasis Treatment market segmented?

The vulvovaginal candidiasis treatmentmarket covered in this report is segmented –
1) By Drug Class: Clotrimazole; Nystatin; Fluconazole; Ketoconazole; Terbinafine; Terconazole; Other Drug Classes
2) By Route Of Administration: Oral; Intravenous; Topical
3) By Distribution Channel: Hospital Pharmacy ; Retail Pharmacy; Online Pharmacy Subsegments:
1) By Clotrimazole: Over-the-Counter (OTC) Medications; Prescription Medications
2) By Nystatin: Monotherapy; Combination Therapy
3) By Fluconazole: Single-Dose Therapy; Multi-Dose Therapy
4) By Ketoconazole: Short-Term Treatment; Long-Term Treatment
5) By Terbinafine: Systemic Treatment; Topical Treatment
6) By Terconazole: Low-Dose Therapy; High-Dose Therapy
7) By Other Drug Classes: Azole Antifungals; Polyene Antifungals; Novel Therapeutics For further insights on this market, request a sample here

Which region has the largest share of the Vulvovaginal Candidiasis Treatment market? What are the other regions covered in the report?

North America was the largest region in the vulvovaginal candidiasis treatment market in 2024. The regions covered in the vulvovaginal candidiasis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the Vulvovaginal Candidiasis Treatment market?

What are the key trends in the Vulvovaginal Candidiasis Treatment market?

Major trends in this market include Innovative Approaches In Non-Azole Medications For Fungal Infections. For further insights on this market, request a sample here.